Устойлівасць да антыбіётыкаў у прыватнасці, грамотріцательных бактэрый, ледзь не стварыла крызісную сітуацыю. Новы антыбіётык зосурабалпін (RG6006) шматабяцальны. У даклінічных даследаваннях было ўстаноўлена, што ён эфектыўны супраць устойлівых да лекаў, грамотріцательных бактэрый CRAB.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of антыбіётыкі to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of антыбіётык супраціў.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available антыбіётыкі. There is an urgent need for an effective антыбіётык against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective антыбіётык. A progress towards this goal has been reported.
Scientists have identified a novel class of антыбіётыкі namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Зосурабалпін (RG6006) ёсць антыбіётык candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-клінічны trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame антыбіётык-resistance mechanism of CARB suggesting Зосурабалпин мае патэнцыял.
Hence, human клінічны trials have been initiated to check for safety and efficacy Зосурабалпин пры лячэнні інвазівных інфекцый, выкліканых CRAB.
***
Спасылкі:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel антыбіётык class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Хаўзэр С., і інш 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Клінічны Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
